Psychedelics for treatment resistant depression: are they game changers?

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013. ISBN:978-0-89042-576-3
   Google Scholar
• Bromet E, Andrade LH, Hwang I et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):1–16. doi: 10.1186/1741-7015-9-90
   PubMed Web of Science ®Google Scholar
• Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National epidemiologic survey on alcoholism and related conditions. Arch Gen Psychiatry. 2005;62(10):1097–1106. doi: 10.1001/archpsyc.62.10.1097
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLOS Med. 2013;10(11):e1001547. doi: 10.1371/journal.pmed.1001547
   PubMed Web of Science ®Google Scholar
• World Health Organization. Depression and other common mental disorders: global health estimates 2017. [cited Jul 21 2023]. Available from: https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf
   Google Scholar
• Greenberg PE, Fournier A-A, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):5356. doi: 10.4088/JCP.14m09298
   Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Depression in adults: treatment and management 2022. [cited Jul 21 2023]. Available from: https://www.nice.org.uk/guidance/ng222
   Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry. 2006;163(11):1905–1917. doi: 10.1176/ajp.2006.163.11.1905
   PubMed Web of Science ®Google Scholar
• Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62:10–17.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210. doi: 10.1016/j.jad.2018.06.045
   PubMed Web of Science ®Google Scholar
• Shah D, Allen L, Zheng W, et al. Economic burden of treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder in the US. PharmacoEconomics. 2021 Jun;39(6):639–651. doi: 10.1007/s40273-021-01029-2
   PubMed Web of Science ®Google Scholar
• Bergfeld IO, Mantione M, Figee M, et al. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362–367. doi: 10.1016/j.jad.2018.04.016
   PubMed Web of Science ®Google Scholar
• Corral R, Alessandria H, Agudelo Baena LM, et al. Suicidality and quality of life in treatment-resistant depression patients in Latin America: secondary interim analysis of the TRAL study. Front Psychiatry. 2022;13:812938. doi: 10.3389/fpsyt.2022.812938
   PubMedGoogle Scholar
• Scott F, Hampsey E, Gnanapragasam S, et al. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. J Psychopharmacol. 2023 Mar;37(3):268–278. doi: 10.1177/02698811221104058
   PubMed Web of Science ®Google Scholar
• Nuñez NA, Joseph B, Pahwa M, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. J Affect Disord. 2022;302:385–400. doi: 10.1016/j.jad.2021.12.134
   PubMed Web of Science ®Google Scholar
• Panariello F, Kasper S, Zohar J, et al. Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting. World J Biol Psychiatry. 2023 Jun;24(5):439–448. doi: 10.1080/15622975.2022.2134588
   PubMed Web of Science ®Google Scholar
• Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;369–388. doi: 10.2147/PPA.S29716
   PubMed Web of Science ®Google Scholar
• Perez N, Langlest F, Mallet L, et al. Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023 Aug 7;76:61–76. doi: 10.1016/j.euroneuro.2023.07.011
   PubMed Web of Science ®Google Scholar
• Li NX, Hu YR, Chen WN, et al. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affect Disord. 2022 Jan 1;296:26–34. doi: 10.1016/j.jad.2021.09.041
   PubMed Web of Science ®Google Scholar
• Ko K, Kopra EI, Cleare AJ, et al. Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis. J Affect Disord. 2022;322:194–204. doi: 10.1016/j.jad.2022.09.168
   PubMed Web of Science ®Google Scholar
• Nichols DE, Barker EL. Psychedelics. Pharmacol Rev. 2016;68(2):264–355. doi: 10.1124/pr.115.011478
   PubMed Web of Science ®Google Scholar
• Passie T, Seifert J, Schneider U, et al. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357–364
   PubMed Web of Science ®Google Scholar
• Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61(3):364–381. doi: 10.1016/j.neuropharm.2011.01.017
   PubMed Web of Science ®Google Scholar
• González-Maeso J, Weisstaub NV, Zhou M, et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53(3):439–452. doi: 10.1016/j.neuron.2007.01.008
   PubMed Web of Science ®Google Scholar
• Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacol. 2019;44(7):1328–1334. doi: 10.1038/s41386-019-0324-9
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–3902. doi: 10.1097/00001756-199812010-00024
   PubMed Web of Science ®Google Scholar
• Erkizia-Santamaría I, Alles-Pascual R, Horrillo I, et al. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomed Pharmacother. 2022;154:113612. doi: 10.1016/j.biopha.2022.113612
   PubMed Web of Science ®Google Scholar
• Rickli A, Moning OD, Hoener MC, et al. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26(8):1327–1337. doi: 10.1016/j.euroneuro.2016.05.001
   PubMed Web of Science ®Google Scholar
• Brown RT, Nicholas CR, Cozzi NV, et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet. 2017;56(12):1543–1554. doi: 10.1007/s40262-017-0540-6
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627. doi: 10.1016/S2215-0366(16)30065-7
   PubMed Web of Science ®Google Scholar
• MacCallum CA, Lo LA, Pistawka CA, et al. Therapeutic use of psilocybin: practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217. doi: 10.3389/fpsyt.2022.1040217
   PubMed Web of Science ®Google Scholar
• Goldin D, Salani D. Ayahuasca: what healthcare providers need to know. J Addict Nurs. 2021;32(2):167–173. doi: 10.1097/JAN.0000000000000405
   PubMed Web of Science ®Google Scholar
• Callaway JC, Raymon LP, Hearn WL, et al. Quantitation of N, N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. J Anal Toxicol. 1996;20(6):492–497
   PubMed Web of Science ®Google Scholar
• McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther. 2004;102(2):111–129. doi: 10.1016/j.pharmthera.2004.03.002
   PubMed Web of Science ®Google Scholar
• Halberstadt AL, Nichols DE, Geyer MA. Behavioral effects of α, α, β, β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacol (Berl). 2012;221:709–718. doi: 10.1007/s00213-011-2616-6
   PubMed Web of Science ®Google Scholar
• De Gregorio D, Enns JP, Nuñez NA, et al. D-lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res. 2018;242:69–96. doi: 10.1016/bs.pbr.2018.07.008
   PubMed Web of Science ®Google Scholar
• Egan CT, Herrick-Davis K, Miller K, et al. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacol (Berl). 1998;136(4):409–414
   PubMed Web of Science ®Google Scholar
• Passie T, Halpern JH, Stichtenoth DO, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295–314. doi: 10.1111/j.1755-5949.2008.00059.x
   PubMed Web of Science ®Google Scholar
• Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. 2018;142:200–218. doi: 10.1016/j.neuropharm.2017.12.040
   PubMed Web of Science ®Google Scholar
• Vamvakopoulou IA, Narine KA, Campbell I, et al. Mescaline: the forgotten psychedelic. Neuropharmacology. 2022;222:109294. doi: 10.1016/j.neuropharm.2022.109294
   PubMed Web of Science ®Google Scholar
• Monte AP, Waldman SR, Marona-Lewicka D, et al. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem. 1997;40(19):2997–3008. PMID: 9301661. doi: 10.1021/jm970219x
   PubMed Web of Science ®Google Scholar
• Cassels BK, Sáez-Briones P. Dark classics in chemical neuroscience: mescaline. ACS Chem Neurosci. 2018;9(10):2448–2458. doi: 10.1021/acschemneuro.8b00215
   PubMed Web of Science ®Google Scholar
• Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (Mdma,“ecstasy”). Pharmacol Rev. 2003;55(3):463–508. doi: 10.1124/pr.55.3.3
   PubMed Web of Science ®Google Scholar
• Battaglia G, Brooks BP, Kulsakdinun C, et al. Pharmacologic profile of MDMA (3, 4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol. 1988;149(1–2):159–163
   PubMed Web of Science ®Google Scholar
• Dunlap LE, Andrews AM, Olson DE. Dark classics in chemical neuroscience: 3, 4-methylenedioxymethamphetamine. ACS Chem Neurosci. 2018;9(10):2408–2427. doi: 10.1021/acschemneuro.8b00155
   PubMed Web of Science ®Google Scholar
• Liechti ME, Saur MR, Gamma A, et al. Psychological and physiological effects of MDMA (“ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23(4):396–404. doi: 10.1016/S0893-133X(00)00126-3
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637–1648. doi: 10.1056/NEJMoa2206443
   PubMed Web of Science ®Google Scholar
• Rucker JJ, Jelen LA, Flynn S, et al. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol. 2016;30(12):1220–1229. doi: 10.1177/0269881116679368
   PubMed Web of Science ®Google Scholar
• Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213(1–2):93–118. doi: 10.1007/s00429-008-0189-x
   PubMed Web of Science ®Google Scholar
• Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 2009;5:433–449. doi: 10.2147/ndt.s5700
   PubMed Web of Science ®Google Scholar
• Vrshek-Schallhorn S, Doane LD, Mineka S, et al. The cortisol awakening response predicts major depression: predictive stability over a 4-year follow-up and effect of depression history. Psychol Med. 2013;43(3):483–493 doi: 10.1017/S0033291712001213
   PubMed Web of Science ®Google Scholar
• Zunszain PA, Hepgul N, Pariante CM. Inflammation and depression. Curr Top Behav Neurosci. 2013:135–151. doi: 10.1007/7854_2012_211
   Google Scholar
• Blier P. Altered function of the serotonin 1A autoreceptor and the antidepressant response. Neuron. 2010;65(1):1–2. doi: 10.1016/j.neuron.2009.12.028
   PubMed Web of Science ®Google Scholar
• Van Oekelen D, Luyten WH, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 2003;72(22):2429–2449. doi: 10.1016/s0024-3205(03)00141-3
   PubMed Web of Science ®Google Scholar
• Commons KG, Linnros SE. Delayed antidepressant efficacy and the desensitization hypothesis. ACS Chem Neurosci. 2019;10(7):3048–3052. doi: 10.1021/acschemneuro.8b00698
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138–2143. doi: 10.1073/pnas.1119598109
   PubMed Web of Science ®Google Scholar
• Ling S, Ceban F, Lui LM, et al. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs. 2022;36(1):17–30. doi: 10.1007/s40263-021-00877-y
   PubMed Web of Science ®Google Scholar
• Pilc A, Machaczka A, Kawalec P, et al. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opin Drug Discov. 2022 Oct;17(10):1131–1146. doi: 10.1080/17460441.2022.2111415
   PubMed Web of Science ®Google Scholar
• Liu X, Zhu H, Gao H, et al. Gs signaling pathway distinguishes hallucinogenic and nonhallucinogenic 5-HT2AR agonists induced head twitch response in mice. Biochem Biophys Res Commun. 2022;598:20–25. doi: 10.1016/j.bbrc.2022.01.113
   PubMed Web of Science ®Google Scholar
• López-Giménez JF, González-Maeso J. Hallucinogens and serotonin 5-HT 2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;45–73. doi: 10.1007/7854_2017_478
   PubMedGoogle Scholar
• Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42(11):929–942. doi: 10.1016/j.tips.2021.08.003
   PubMed Web of Science ®Google Scholar
• Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double‐blind, placebo‐controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 2022;111(4):886–895. doi: 10.1002/cpt.2487
   PubMed Web of Science ®Google Scholar
• De Vos CM, Mason NL, Kuypers KP. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021;12:724606. doi: 10.3389/fpsyt.2021.724606
   PubMed Web of Science ®Google Scholar
• Liu PZ, Nusslock R. Exercise-mediated neurogenesis in the hippocampus via BDNF. Front Neurosci. 2018;12:52. doi: 10.3389/fnins.2018.00052
   PubMed Web of Science ®Google Scholar
• Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089–1093. doi: 10.1038/nn1971
   PubMed Web of Science ®Google Scholar
• Vargas MV, Dunlap LE, Dong C, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379(6633):700–706. doi: 10.1126/science.adf0435
   PubMed Web of Science ®Google Scholar
• Almeida R, Galvão A, Da Silva FS, et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol query. 2019;10:1234. doi: 10.3389/fpsyg.2019.01234
   PubMed Web of Science ®Google Scholar
• De Veen BT, Schellekens AF, Verheij MM, et al. Psilocybin for treating substance use disorders? Expert Rev Neurother. 2017;17(2):203–212. doi: 10.1080/14737175.2016.1220834
   PubMed Web of Science ®Google Scholar
• Galvao ACDM, De Almeida RN, Silva EADS, et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psychiatry. 2018;9:185. doi: 10.3389/fpsyt.2018.00185
   PubMed Web of Science ®Google Scholar
• Hasler F, Grimberg U, Benz MA, et al. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacol (Berl). 2004;172(2):145–156. doi: 10.1007/s00213-003-1640-6
   PubMed Web of Science ®Google Scholar
• Strajhar P, Schmid Y, Liakoni E, et al. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol. 2016;28(3). doi: 10.1111/jne.12374
   PubMed Web of Science ®Google Scholar
• Dela Torre R, Farre M, Roset P, et al. Pharmacology of MDMA in humans. Annals Of The New York Academy Of Sciences. 2000;914(1):225–237
   PubMedGoogle Scholar
• Uthaug MV, Lancelotta R, Szabo A, et al. Prospective examination of synthetic 5-methoxy-N, N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacol (Berl). 2020;237(3):773–785. doi: 10.1007/s00213-019-05414-w
   PubMed Web of Science ®Google Scholar
• Seifritz E, Baumann P, Müller MJ, et al. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. Neuropsychopharmacology. 1996;14(4):253–263
   PubMed Web of Science ®Google Scholar
• Von Bardeleben U, Steiger A, Gerken A, et al. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol. 1989;4 Suppl 1:1–5.
   PubMed Web of Science ®Google Scholar
• Deuschle M, Hamann B, Meichel C, et al. Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. J Clin Psychopharmacol. 2003;23(2):201–205. doi: 10.1097/00004714-200304000-00014
   PubMed Web of Science ®Google Scholar
• Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol. 2007;19(3):213–226. doi: 10.1111/j.1365-2826.2006.01516.x
   PubMed Web of Science ®Google Scholar
• Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363–375. doi: 10.1080/09540261.2018.1481827
   PubMed Web of Science ®Google Scholar
• Galvão-Coelho NL, de Menezes Galvão AC, de Almeida RN, et al. Changes in inflammatory biomarkers are related to the antidepressant effects of ayahuasca. J Psychopharmacol. 2020;34(10):1125–1133. doi: 10.1177/0269881120936486
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):1–11. doi: 10.1038/s41598-017-13282-7
   PubMedGoogle Scholar
• Drevets WC, Videen TO, Price JL, et al. A functional anatomical study of unipolar depression. J Neurosci. 1992;12(9):3628–3641
   PubMed Web of Science ®Google Scholar
• Sanches RF, de Lima Osório F, Dos Santos RG, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36(1):77–81. doi: 10.1097/JCP.0000000000000436
   PubMed Web of Science ®Google Scholar
• Friesen P. Psychosis and psychedelics: historical entanglements and contemporary contrasts. Transcult Psychiatry. 2022;59(5):592–609. doi: 10.1177/13634615221129116
   PubMed Web of Science ®Google Scholar
• Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord. 2019;258:11–24. doi: 10.1016/j.jad.2019.07.076
   PubMed Web of Science ®Google Scholar
• Swanson LR. Unifying theories of psychedelic drug effects. Front Pharmacol. 2018;9:172. doi: 10.3389/fphar.2018.00172
   PubMed Web of Science ®Google Scholar
• Roseman L, Haijen E, Idialu-Ikato K, et al. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol. 2019;33(9):1076–1087. doi: 10.1177/0269881119855974
   PubMed Web of Science ®Google Scholar
• Dolder PC, Schmid Y, Müller F, et al. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology. 2016;41(11):2638–2646. doi: 10.1038/npp.2016.82
   PubMed Web of Science ®Google Scholar
• Pokorny T, Preller KH, Kometer M, et al. Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol. 2017;20(9):747–757. doi: 10.1093/ijnp/pyx047
   PubMed Web of Science ®Google Scholar
• Barrett FS, Griffiths RR. Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci. 2018:36:393–430. doi: 10.1007/7854_2017_474
   PubMedGoogle Scholar
• Kometer M, Schmidt A, Bachmann R, et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72(11):898–906. doi: 10.1016/j.biopsych.2012.04.005
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Friston KJ, Barker EL. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71(3):316–344. doi: 10.1124/pr.118.017160
   PubMed Web of Science ®Google Scholar
• Nutt D, Erritzoe D, Carhart-Harris R. Psychedelic psychiatry’s brave new world. Cell. 2020;181(1):24–28. doi: 10.1016/j.cell.2020.03.020
   PubMed Web of Science ®Google Scholar
• van Elk M, Yaden DB. Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neurosci Biobehav Rev. 2022;104793. doi: 10.1016/j.neubiorev.2022.104793
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu A, Richards WA. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Int Rev Psychiatry. 2018;30(4):291–316. doi: 10.1080/09540261.2018.1486289
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol (Berl). 2006;187(3):268–283. doi: 10.1007/s00213-006-0457-5
   PubMed Web of Science ®Google Scholar
• Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020;4(2):563–567. doi: 10.1021/acsptsci.0c00192
   PubMedGoogle Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;88:105906. doi: 10.1136/bmj.n71
   Web of Science ®Google Scholar
• Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry. 2017 Jan 1;74(1):9–10. doi: 10.1001/jamapsychiatry.2016.2586
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10
   PubMedGoogle Scholar
• Campbell M. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020. l6890. doi: 10.1136/bmj.l6890
   PubMedGoogle Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.doi: 10.1136/bmj.i4919
   PubMed Web of Science ®Google Scholar
• Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Day CM, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacol (Berl). 2018;235(2):399–408. doi: 10.1007/s00213-017-4771-x
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacol. 2023;48(10):1–8. doi: 10.1038/s41386-023-01648-7
   PubMed Web of Science ®Google Scholar
• D’Souza DC, Syed SA, Flynn LT, et al. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacol. 2022;47(10):1854–1862. doi: 10.1038/s41386-022-01344-y
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. doi: 10.1017/S0033291718001356
   PubMed Web of Science ®Google Scholar
• Reckweg JT, van Leeuwen CJ, Henquet C, et al. A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry. 2023;14:1133414. doi: 10.3389/fpsyt.2023.1133414
   PubMed Web of Science ®Google Scholar
• Holze F, Gasser P, Müller F, et al. Lysergic acid diethylamide–assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023;93(3):215–223. doi: 10.1016/j.biopsych.2022.08.025
   PubMed Web of Science ®Google Scholar
• Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513–520. doi: 10.1097/NMD.0000000000000113
   PubMed Web of Science ®Google Scholar
• Agin-Liebes G, Haas TF, Lancelotta R, et al. Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes. ACS Pharmacol Transl Sci. 2021;4(2):543–552. doi: 10.1021/acsptsci.1c00018
   PubMedGoogle Scholar
• Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2023;27(6):1025–1033. doi: 10.1038/s41591-021-01336-3
   Web of Science ®Google Scholar
• Ot’alora GM, Grigsby J, Poulter B, et al. 3, 4-methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol. 2018;32(12):1295–1307. doi: 10.1177/0269881118806297
   PubMed Web of Science ®Google Scholar
• Wolfson PE, Andries J, Feduccia AA, et al. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020;10(1):20442. doi: 10.1038/s41598-020-75706-1
   PubMed Web of Science ®Google Scholar
• Majumder I, White JM, Irvine RJ. Antidepressant‐like effects of ecstasy in subjects with a predisposition to depression. Addict Behav. 2012;37(10):1189–1192. doi: 10.1016/j.addbeh.2012.05.022
   PubMed Web of Science ®Google Scholar
• Jones GM, Nock MK. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. J Psychopharmacol. 2022;36(1):57–65. doi: 10.1177/02698811211066714
   PubMed Web of Science ®Google Scholar
• Hartogsohn I. Constructing drug effects: a history of set and setting. Drug Sci Policy Law. 2017;3:2050324516683325. doi: 10.1177/2050324516683325
   Google Scholar
• Studerus E, Gamma A, Kometer M, et al. Prediction of psilocybin response in healthy volunteers. PLoS One. 2012;7(2):e30800. doi: 10.1371/journal.pone.0030800
   PubMed Web of Science ®Google Scholar
• Modlin NL, Miller TM, Rucker JJ, et al. Optimizing outcomes in psilocybin therapy: considerations in participant evaluation and preparation. J Affect Disord. 2023;326:18–25. doi: 10.1016/j.jad.2023.01.077
   PubMed Web of Science ®Google Scholar
• Murphy R, Kettner H, Zeifman R, et al. Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front Pharmacol. 2022;12:788155. doi: 10.3389/fphar.2021.788155
   PubMed Web of Science ®Google Scholar
• Nayak S, Johnson MW. Psychedelics and psychotherapy. Pharmacopsychiatry. 2021;54(4):167–175. doi: 10.1055/a-1312-7297
   PubMedGoogle Scholar
• Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. doi: 10.1056/NEJMoa2032994
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79(10):953–962. doi: 10.1001/jamapsychiatry.2022.2096
   PubMed Web of Science ®Google Scholar
• Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(9):1133–1152. doi: 10.1080/17512433.2021.1933434
   PubMed Web of Science ®Google Scholar
• Butler M, Jelen L, Rucker J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacol (Berl). 2022;239(10):3047–3055. doi: 10.1007/s00213-022-06221-6
   PubMed Web of Science ®Google Scholar
• Bender D, Hellerstein DJ. Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacol (Berl). 2022;239(6):1–26. doi: 10.1007/s00213-021-06049-6
   Web of Science ®Google Scholar
• Borissova A, Rucker JJ. The development of psilocybin therapy for treatment-resistant depression: an update. BJPsych Bull. 2023;26:1–7. doi: 10.1192/bjb.2023.25
   Google Scholar
• Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Curr Behav Neurosci. 2018;36:333–360. doi: 10.1007/7854_2016_457
   PubMedGoogle Scholar
• Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268–1278. doi: 10.1177/0269881116662634
   PubMed Web of Science ®Google Scholar
• Aday JS, Davis AK, Mitzkovitz CM, et al. Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol Transl Sci. 2021;4(2):424–435. doi: 10.1021/acsptsci.1c00014
   PubMedGoogle Scholar
• Haijen EC, Kaelen M, Roseman L, et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol. 2018;9:897. doi: 10.3389/fphar.2018.00897
   PubMed Web of Science ®Google Scholar
• Kopra EI, Ferris JA, Winstock AR, et al. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965–973. doi: 10.1177/02698811221084063
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry. 2000;61(10):712–721. doi: 10.4088/jcp.v61n1002
   PubMed Web of Science ®Google Scholar
• Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs. 1998;30(4):367–369. doi: 10.1080/02791072.1998.10399712
   PubMed Web of Science ®Google Scholar
• Peck SK, Shao S, Gruen T, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023;29(8):1–7. doi: 10.1038/s41591-023-02455-9
   PubMed Web of Science ®Google Scholar
• Der Meer PB V, Fuentes JJ, Kaptein AA, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023;14:1134454. doi: 10.3389/fpsyt.2023.1134454
   PubMed Web of Science ®Google Scholar
• Zeifman RJ, Wagner AC. Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. J Contextual Behav Sci. 2020;15:1–11. doi: 10.1016/j.jcbs.2019.11.001
   Web of Science ®Google Scholar
• Aaronson S, Miller T, Rudow S, et al. 96. An open label study of synthetic psilocybin in bipolar type II depression. Biol Psychiatry. 2023;93(9):S132–S133. doi: 10.1016/j.biopsych.2023.02.336
   Web of Science ®Google Scholar